Caroline is Senior Vice President and Head of Genetics and Target Discovery at Quotient Therapeutics, a Flagship Pioneering Company, where she is also a Senior Fellow. At Quotient, Caroline provides leadership and strategic direction to the genomics platform, data science, and data infrastructure teams. She also oversees all indication selection and target assessments and triage. Prior to Quotient, Caroline was Vice President and Head of the Genome and Biomarkers Science group at Merck. There, she directed a global, cross-functional team capitalizing on genetics, genomics, data science, and biomarkers to drive drug discovery and development across the entire R&D pipeline. Prior to entering industry, Caroline was a Tenured Senior Scientist in the Laboratory for Population and Metabolic Health, as well as Deputy Branch Chief in the Population Sciences Branch of the National Heart, Lung, and Blood (NHLBI) Division of Intramural Research. There, she developed and directed a research program focused on diabetes, obesity, and kidney disease in the Framingham Heart Study. Caroline received her BA in English from the University of Michigan, her MPH in Epidemiology from the University of Michigan School of Public Health, and her MD from the University of Pennsylvania. She completed her internship and residency in Internal Medicine at the Brigham and Women’s Hospital in Boston, MA, where she also completed a fellowship in Endocrinology. Caroline has published over 400 original, peer-reviewed papers, is an inducted member of the American Society for Clinical Investigators, was named on the Thomson Reuters “World’s Most Influential Scientific Minds” from 2014-2020, and is ranked the 18th top female scientist in the world by Research.com. She also maintained an active diabetology clinical practice at the Brigham and Women’s Hospital until 2022. Caroline lives outside of Boston, MA with her husband, 3 children, and a very small but mighty dog. She enjoys running, swimming, reading, and traveling when she’s not working.